Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

manilatimes.net · 2026-10-20

-- Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex

TickrTrends take: Mestag Therapeutics, a company in which Johnson & Johnson has invested, announced board appointments that could influence the development trajectory of its pipeline candidates. Given TickrTrends' current assessment that JNJ is overvalued, investors should monitor whether Mestag's strategic leadership changes generate sufficient clinical or commercial progress to justify JNJ's current valuation in the Healthcare sector. Any meaningful advancement in Mestag's programs would need to demonstrate substantial value creation to address the overvaluation concern at the parent investment level.

Read the full story at manilatimes.net →